Hi
Sorry Stuart, i completely forgot to pass on your best wishes.
well as we thought, Philip will move to Revlimid next week. What we didn’t expect was Dr Boyd implied that the evidence for the benefits of an allo outweighing the risk are not proven sufficiently for him to recommend it. I am not sure why. he said he was at the european haemotological conference recently and spoke to Dr Kwee from UCH london, and said she does not do allos at all now, but sometimes refers people for them, as a first option. He thought that the only place really doing lots at the moment is in Leeds. he said that the mortality /morbidity risks were so high, and the fact that you can’t predict whether you’d end up lucky, or dead, that there are few people for whom they are suitable. A complete change from his point of view last time. i am pleased that he’s willing to learn and change his opinion as the evidence appears, but it does add to that rollercoaster feeling!
So we have arranged for an appointment at the Marsden as we’d like a consultation there, but it seems that an allo may be off the table, particularly as the Marsden were against it last time it was mentioned.
That’s almost a relief as we were dreading it, but he then threw in the bombshell that he doesn’t expect the revlimid to last much longer than a year, and pomalidomide less than that. He said he’d expect to get Philip 2 years but can’t really predict much more.
I so so so hope that there are some more drugs around soon.